The first childhood case with coexisting Hashimoto thyroiditis, vitiligo and autoimmune hepatitis

Melikşah Keskin¹, Şenay Savaş-Erdeve¹, Ferda Özbay-Hoşnut², Erdal Kurnaz¹, Semra Çetinkaya¹, Zehra Aycan¹
¹Clinic of Pediatric Endocrinology and ²Pediatric Gastroenterology Clinic, Dr. Sami Ulus Obstetrics and Gynecology and Pediatrics Training and Research Hospital, Ankara, Turkey.
E-mail: meliksah keskin@hotmail.com
Received: 19th October 2015, Revised: 5th April 2016, Accepted: 9th June 2016


Hashimoto thyroiditis (HT) is the most common pediatric autoimmune endocrine disorder. It results in autoimmunity-mediated thyroid gland destruction and is an organ-specific, typical autoimmune disease. The presence of antithyroid antibodies and the typical pattern on ultrasonography indicate the diagnosis. The patient may be suffering from various thyroid problems from transient hyperthyroidism to overt hypothyroidism at presentation¹². The pathology consists of lymphocytic cell infiltration, follicular atrophy and hyperemia in the thyroid together with atrophy of tissue and follicular cell oncocytic metaplasia. The incidence is much higher in patients with other autoimmune disorders such as diabetes mellitus type 1, systemic lupus erythematosus, rheumatoid arthritis and Addison’s disease, classified as autoimmune polyendocrine syndromes³.

Autoimmune hepatitis (AIH) can be seen at any age and is generally a progressive and chronic hepatitis of unknown etiology. The probable etiology of this multifactorial polygenic disorder is thought to be the interaction between a trigger and various environmental factors in an already genetically susceptible individual. Most patients are female and the clinical presentation can vary from minor symptoms all the way to acute liver failure⁴.
The coexistence of HT, AIH and vitiligo is quite rare and has previously been reported in only one adult case as far as we are aware. However, this coexistence may not be as rare as it is thought to be.

Case Report

A 14-year-old male patient who was being followed-up at the dermatology department for vitiligo presented with symptoms of swelling of the neck and fatigue. His history revealed that he had been followed-up for vitiligo since the age of 8 years and did not use any medication. There was no kinship between the parents and no significant family history. The physical examination of the patient at admission revealed a fully cooperative patient in good general condition. Body temperature was 36.5˚C, apical heart peak 86/minute, respiratory rate 16/minute and blood pressure 105/70 mmHg. Bilateral thyroid lobes were palpable and hypopigmented lesions were present on the entire body. There was no organomegaly and other physical examination findings were normal. Laboratory investigations revealed hemoglobin 13.3 g/dl (9.5-14.8), WBC 5.600 ×10³/μL (5.1-15.5), platelet 173 ×10³/μL (159-353), blood urea nitrogen (BUN) 6 mg/dl (0-23), and creatinine 0.61 mg/dl (0.6-1.2). The serum TSH was 6.44 μIU/ml (0.6-5.5), free-T4 1.11 ng/dl (0.8-1.9), anti-thyroid peroxidase (TPO) 1080 IU/ml (0-60), and anti-thyroglobulin (anti-TG) 64.7 (0-60) IU/ml. Thyroid ultrasonography revealed a thyroid volume of 9.9 cm³ and a heterogeneous appearance secondary to hypoechogenic infiltration in both thyroid lobes. The patient was diagnosed with HT with these findings. The serum aspartate aminotransferase level (AST) was 63 U/L (0-27), alanine aminotransferase (ALT) 74 U/L (<29), alkaline phosphatase (ALP) 106, glutamyltranspeptidase (GGT) 21 IU/L (20-64), total bilirubin 0.6, indirect bilirubin 0.3, total protein 8 gr/dl (6.4-8.3), and albumin 4.2 g/dl (3-4.8). Previous laboratory results of the patients requested for other complaints revealed elevated transaminase levels for over six months. The relevant requested tests revealed that hepatitis B, hepatitis C, cytomegalovirus (CMV) and Ebstein-Barr (EBV) serologies were negative. The serum alpha-1 antitrypsin level was normal and celiac serology (tissue transglaminase IgA and IgG, anti-endomyccium Ig A) was negative. Serum ceruloplasmin level was 29.9 mg/dl (22-58) and copper level in 24-hour urine 12.7μg/day (3-35). The eye examination was normal. The patients’ serum Ig G level was 2310 mg/dl (854-1750), IgM 87.5 mg/dl (78.8-370), C3 1.01 g/l (0.83-1.77), C4 0.172 g/l (0.12-0.4), positive for anti-nuclear antibodies (ANA) (1/80 titer) and anti-double-stranded DNA (Anti-ds-DNA) (1/160 titer) and negative for anti-liver kidney microsomal antibodies (LKM-1) and anti-smooth muscle antibodies (ASMA). Minimal hepatomegaly was found on ultrasonographic analysis of the liver and a fine granular appearance was observed in the liver parenchyma. There was portal and periportal hepatitis with plasma cell at the interface, lymphocytic-plasmacytic infiltration and mild fibrosis on histology evaluation. Magnetic resonance cholangiopancreatography (MRCP) was normal. These results (ANA ≥1:80 was 2 points, Ig G level >1.10-fold was 2 points, typical autoimmune hepatitis findings on liver biopsy was 2 points, exclusion of viral hepatitis was 2 points) indicated a total autoimmune hepatitis score of 8 points and the patient was diagnosed with autoimmune hepatitis.

The diagnosis was HT, AIH, and vitiligo. Levothyroxine was started at a dose of 50 mg/day, prednisolone 2 mg/kg/day and azathioprine (AZT) 1 mg/kg. The liver enzymes returned to normal levels on the tenth day of treatment. Prednisolone was tapered slowly to a maintenance dose of 5 mg/day whereas AZT was continued at the same dose following remission. The transaminase levels were normal and autoantibodies negative during 3 years of follow-up.

Discussion

Hakaru Hashimoto described HT in 1912. However, it was in the 1950s that its relationship with autoimmunity was shown. HT development is not fully understood but requires the combination of an immune defect, genetic susceptibility and environmental factors. The condition frequently coexists with other autoimmune diseases that include type-1 insulin-dependent diabetes, coeliac disease, alopecia, and vitiligo. Our case presented with fatigue while being followed-up with a...
diagnosis of vitiligo and was diagnosed with HT and AIH. Hashimoto thyroiditis (HT) coexistence with AIH is rare and it was reported only in 2 previous patients as far as we know. The first case was a 44-year-old male who was diagnosed with AIH as a result of high liver function tests performed for fatigue while being followed-up with HT. The laboratory investigations revealed ALT of 977 IU/L and AST 1840 IU/L. Anti-nuclear antibody was found to be positive after tests for hepatitis A, B, C, D, E, CMV, and EBV, some of the conditions that can cause acute hepatitis, were all negative. Minimal hepatomegaly was observed on liver ultrasonography. Liver biopsy showed portal and periportal hepatitis, dilated portal vein and lymphoplasmacytic infiltration. The patient was diagnosed with AIH with these findings and started prednisolone treatment at a dose of 25 mg/day. ALT and ALT levels were reported to return to normal afterwards.

The second case in the literature is a 52-year-old male patient who presented with symptoms of fatigue, weakness, itching and jaundice while being followed-up with HT and vitiligo. The laboratory analyses revealed ALT 278 IU/L, AST 228 IU/L, ALP 512 IU/L, GGT 1315 IU/L, Ig G 36.6 g/L (7-16) and Ig M 3.5 g/L (0.4-2.3). ANA, ASMA, Anti-ds DNA were positive. Liver biopsy results were consistent with AIH and primary biliary cirrhosis. The patient was started 30 mg/prednisolone, 50 mg azathioprine and 1250 mg ursodeoxycholic acid (UDCA) daily. Following remission, the prednisolone was decreased to 5 mg/day maintenance dose and the azathioprine and UDCA were continued at the same dose.

The estimated prevalence of AIH in the Western population is 10–50/100,000, making it fairly rare. It has a strong predominance for middle-aged women. The female: male ratio is 4:1 for type 1 AIH and 10:1 for type 2 AIH. However, all 3 cases including our case where HT and AIH coexist are males. The other patients were diagnosed at adulthood but our case was diagnosed at childhood. The presentation signs can be nonspecific and include fatigue, lethargy, nausea, abdominal pain and itching of varying severity. Our case presented with fatigue and was diagnosed with AIH following the investigations for repeatedly elevated liver function tests. Many patients also experience arthralgia but have no arthritis. This arthralgia mostly involves the small joints. Our patient did not have this symptom. Physical examination may be normal or reveal hepatomegaly, jaundice and other chronic liver disease symptoms in addition to splenomegaly. There were no chronic liver disease signs in our patient, possibly due to the early diagnosis.

The diagnosis of AIH is based on a series of positive and negative criteria. These include increase in transaminase levels, positive autoantibodies (ANA and/or SMA ≥1:20 in type 1 AIH; anti-LKM1 ≥1/10 and positive anti-LC1 in type 2 AIH; positive anti-SLA in type 1 and 2 AIH), increased serum IgG, interphase hepatitis or multilobular collapse on liver biopsy and exclusion of viral causes, exclusion of Wilson’s Disease and a normal cholangiogram. There are two main types of the disorder according to the autoantibodies present. Type 1 AIH is the classic form and is seen mostly in young females. It is characterized by the presence of ANA and/or anti-SMA and a good response to immunosuppression. Type 2 AIH is characterized by the presence of liver-anti-LKM-1 and is usually associated with thyroid and gastric parietal cell (GPC) antibodies. It usually starts at childhood with a second peak between the ages of 35 and 65 years. It has an acute clinical onset and progresses quickly to cirrhosis with 40-70% of the patients cirrhotic at the time of diagnosis. Response to immunosuppression and the prognosis are not as good as Type-1. Our case was diagnosed as Type 1 AIH. It is known that anti-ds-DNA can be positive in these cases. The clinical and laboratory findings of autoimmune hepatitis and systemic lupus erythematosus cases can be similar, as in our case. Liver biopsy plays a major role in differentiating these two disorders in such cases. The liver biopsy shows characteristic lesions in patients with AIH, as seen in our case, including interface hepatitis, rosetting of hepatocytes, emperipolosis and consecutive to inflammation fibrosis.

Autoimmune hepatitis is known to be associated with primary biliary cirrhosis and primary sclerosing cholangitis. However, there are very few reports on the association of AIH
with autoimmune disorders other than these two conditions. The MRCP of our case was normal. There is only one case in the literature where the coexistence of AIH, primary biliary cirrhosis and vitiligo has been reported. Thyroid disorders (Hashimoto and Graves disease), celiac disease, MS and other autoimmune conditions have been reported to be associated with AIH. Our case was diagnosed with AIH coexisting with HT.

We believe our case is the first to be reported with the diagnosis of HT and coexisting AIH in childhood. Our data suggest that a possible association with AIH should be considered in patients affected by HT with repeated high aminotransferase levels.

REFERENCES